ImageneBio (IMA) Total Liabilities (2020 - 2025)
ImageneBio (IMA) posted Total Liabilities of $19.8 million for Q4 2025, down 5.74% sequentially from $21.0 million in Q3 2025, and up 13.69% YoY from $17.4 million in Q4 2024.
ImageneBio (IMA) Total Liabilities (2020 - 2025) Analysis & Trends
ImageneBio has reported Total Liabilities for 6 years, with the latest figure at $19.8 million in Q4 2025.
- Quarterly Total Liabilities rose 13.69% year-over-year to $19.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19.8 million (up 13.69% YoY) and the FY2025 annual result came in at $19.8 million, up 13.69% from the prior year.
- Total Liabilities slipped to $19.8 million in Q4 2025 per IMA's latest filing, from $21.0 million in the prior quarter.
- Over five years, Total Liabilities peaked at $66.0 million in Q1 2021 and troughed at $10.3 million in Q2 2025.
- A 5-year average of $28.3 million and a median of $21.7 million in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities slumped 59.08% in 2023, then jumped 42.63% in 2025.
- Over 5 years, Total Liabilities stood at $40.0 million in 2021, then slumped by 36.78% to $25.3 million in 2022, then decreased by 11.68% to $22.3 million in 2023, then slipped by 21.88% to $17.4 million in 2024, then advanced by 13.69% to $19.8 million in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $19.8 million, $21.0 million, and $10.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | ImageneBio | 48.60 Mn | -86.75 Mn | - | 19.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 19.84 Mn |
| Sep 30, 2025 | 21.05 Mn |
| Jun 30, 2025 | 10.26 Mn |
| Mar 31, 2025 | 12.59 Mn |
| Dec 31, 2024 | 17.45 Mn |
| Sep 30, 2024 | 14.76 Mn |
| Jun 30, 2024 | 14.63 Mn |
| Mar 31, 2024 | 17.44 Mn |
| Dec 31, 2023 | 22.34 Mn |
| Sep 30, 2023 | 28.15 Mn |
| Jun 30, 2023 | 15.06 Mn |
| Mar 31, 2023 | 17.38 Mn |
| Dec 31, 2022 | 25.29 Mn |
| Sep 30, 2022 | 31.68 Mn |
| Jun 30, 2022 | 36.82 Mn |
| Mar 31, 2022 | 34.79 Mn |
| Dec 31, 2021 | 40.00 Mn |
| Sep 30, 2021 | 58.44 Mn |
| Jun 30, 2021 | 62.57 Mn |
| Mar 31, 2021 | 66.02 Mn |